Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Novartis's vildagliptin and Merck's sitagliptin will achieve blockbuster status by 2014 in the market to treat type 2 diabetes.

"Long-term growth in this market will be sustained by the entry of agents from several new drug classes, particularly the dipeptidyl-peptidase IV (DPP- IV) inhibitor class, which includes vildagliptin and sitagliptin," said Donny Wong, Ph.D., analyst at Decision Resources. "DPP-IV inhibitors are among the most novel agents in late-stage development for the treatment of diabetes."

A new Pharmacor study entitled Type 2 Diabetes also finds that the prevalence of type 2 diabetes will continue to grow because of an aging general population. Prevalent cases in the major pharmaceutical markets are expected to rise from more than 50 million in 2004 to nearly 57 million in 2014.

About Type 2 Diabetes

Type 2 diabetes is a progressive disease of metabolic dysregulation that has become one of the most costly public health problems of the 21st century. The American Diabetes Association estimates that type 2 diabetes is responsible for more than $132 billion annually in direct and indirect medical costs in the United States. Type 2 diabetes is inextricably linked to an aging population and the global pandemics of obesity and metabolic syndrome, which have led to surging prevalence of the disease over the past several decades.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Care Choices HMO Draws Education Groups Away from the Michigan Education Special Services Association, According to Healthleaders-Interstudy

View Now